This disclosure relates generally to compounds, pharmaceutical compositions and methods of use of the compounds and compositions containing them. This disclosure relates more particularly to certain carboxamide compounds and pharmaceutical compositions thereof, and to methods of treating and preventing metabolic disorders such as type II diabetes, atherosclerosis and cardiovascular disease using certain carboxamide compounds. More specifically to compounds of formula (I), compositions containing them and their use in manufacture of medicaments as described herein. Examples of compounds of formula (I) are: tert-butyl 4-(6-(1-(4-(trifluoromethyl)phenyl)piperidin-4-yloxy)benzo[d]oxazole-2-carboxamido)piperidine-1-carboxylate, 4-((5 -(6-( 1 -(4-(trifluoromethyl)phenyl)piperidin-4-yloxy)benzo[d]oxazole-2-carbonyl)-2, 5 -diazabicyclo [2.2.1] heptan-2-yl)methyl)benzamide, N-(1 -(pyri din- 4-ylmethyl)piperidin-4-yl)-5-(1- (4-(trifluoromethyl)phenyl)piperidin-4-yloxy)pyrazine-2-carboxamide, 2-(4-cyanobenzyl)-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide.
